The Federal Trade Commission and Food and Drug Administration sent letters to three companies that advertise supplements containing cannabidiol, commonly known as CBD, about the claims made for their ability to...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: